Answer

IFF Scent recovery drivers, H2 evolution by sub-segment, and 2027 R&D plan

1) Drivers of Scent’s recovery

Management attributes Scent’s recovery to three reinforcing elements: (1) rebuilding growth and share through commercial execution, (2) improved and more targeted R&D capability (pipeline + perfumers + delivery systems), and (3) normalization effects from prior-period comparables and regional volatility in Fine Fragrance.

A. Fine Fragrance: managing Middle East volatility + strong Q4 recovery shape

Management says the team “did a very good job at managing the challenges in the Middle East,” resulting in Fine Fragrance finishing “up slightly positive” rather than the expected “down in Fine Fragrance mid-single digits.” ¹
The company frames the recovery path as “softer Q3” followed by “recovery as we get to Q4 overall,” with Fine Fragrance subject to a “big comp” because “in Q3 last year, Fine Fragrance grew 20%.” ¹
On the directional growth profile for the second half, management indicates Fine Fragrance is expected to be “softer in Q3, but a stronger Q4,” targeting “a stronger Q4… on a second half basis in the mid-single-digit range.” ²

Implication: Fine Fragrance recovery is primarily a risk-management and timing story (volatility management + difficult comparisons in Q3 + improved comps in Q4), rather than a simple linear improvement through the entire second half. ²¹

B. Consumer Fragrance: R&D rebuild + go-to-market + market share gains

Management links Consumer Fragrance performance to rebuilding the “R&D capability [and] go-to-market approach with customers” and driving “market share gains.” ²
Reported momentum: Scent delivered “8% growth” in Q2, with performance driven by “high single-digit increase in Consumer Fragrance” and “double-digit growth in Fragrance Ingredients,” while Fine Fragrance grew “low single digits” inclusive of Middle East impact. ³¹
For the second half, management expects Consumer Fragrance to be in the “low single-digit range,” with the expectation that the “really good Q2 at a high single-digit number… will… normalize… to kind of a low single-digit number” going forward. ²

Implication: Consumer Fragrance’s recovery is supported by capability-building (R&D + commercial engagement) aimed at share gains, but the reported growth rate is expected to decelerate in H2 due to normalization from a strong Q2. ²³

C. Fragrance Ingredients: temporary normalization pressure after a very strong Q2

Management stresses that Fragrance Ingredients growth in Q2 was strong and partly helped by favorable comparisons and product mix execution, but will normalize afterward:

Scent Q2 performance: Fragrance Ingredients “grew north of 20%,” partly due to the year-ago period being “down 10% or more.” ¹
Underlying strength: management also says the team “strategically leveraged the synthetics portfolio to capture more sales due to the macroeconomic environment,” including “some… supply chain disruptions and higher Brent crude prices.” ¹
Forward normalization: management expects growth to “normalize… included in our forecast for the second half of the year,” with growth “shift back towards the higher value-added ingredients versus the traditional synthetics that were really a strong point in Q2.” ¹
Longer-run ingredient strategy: the company also describes a “shift… to higher-value natural products” that is underway; management says this “will take a little bit more time” and is not expected to be the focus “in the second half of this year,” but as it goes into “next year and the year after,” IFF expects “a really strong competitive position.” ²

Implication: The recovery drivers include both (i) tactical capture of sales during macro/supply conditions (synthetics portfolio) and (ii) an intentional transition toward higher-value natural products that supports competitive position over the medium term, even if near-term growth normalizes. ¹²

2) How Fine Fragrance and Consumer Fragrance will evolve in H2

Fine Fragrance (mid-single-digit H2; softer Q3, stronger Q4)

Expected second-half growth: “mid-single-digit range” on a “second half basis.” ²
Timing: “softer in Q3, but a stronger Q4.” ²
Management-specific rationale: Q3 has a heavy comparison because “in Q3 last year, Fine Fragrance grew 20%,” and the Middle East “crisis continues,” leading the company to factor in softer Q3 while “start to see some recovery as we get to Q4 overall.” ¹

Consumer Fragrance (low-single-digit H2; Q2 strength normalizes)

Expected second-half growth: “low single-digit range.” ²
Normalization mechanism: after “a really good Q2 at a high single-digit number,” management expects it “will normalize… to… a low single-digit number… on a go-forward basis.” ²
Strategic support behind the scenes: management emphasizes that the team is rebuilding “R&D capability” and “go-to-market approach with customers” and working toward “market share gains.” ²

3) Plan for R&D to support 2027 (what management says they changed and what it enables)

The excerpts provide a clear statement that R&D capability and pipeline quality have materially improved over the last ~2.5 years, and that the company expects that capability to translate into strong competitive positioning beyond 2026.

A. Current R&D state: pipeline, perfumers, delivery systems, and improved capability

Management highlights that “2.5 years ago” the Scent R&D pipeline “was not what it should have been” and that the company has since “got… a very strong R&D capability” with “great perfumers” developing “leading-edge new Fine Fragrances and Consumer Fragrances,” alongside “a great pipeline of molecules as well as delivery systems.” ⁴

B. What R&D is explicitly intended to accomplish (commercial execution + share gains)

R&D is positioned as a mechanism to rebuild the go-to-market process and regain market share: management explicitly connects “compounds” execution and the rebuilding of “R&D capability” plus “go-to-market approach with customers,” aiming to “drive market share gains.” ²

C. Link to 2027 competitiveness: ingredient strategy maturation + R&D pipeline readiness

For Fragrance Ingredients, management says the shift to “higher-value natural products… is underway,” will “take a little bit more time,” and while not the near-term driver “in the second half of this year,” “as we go into next year and the year after, we believe we’ll have a really strong competitive position.” ²
While the excerpt does not state a year-by-year 2027 budget or specific program names, management’s qualitative plan is: strengthen R&D capability (pipeline/perfumer/delivery systems) and continue execution so that by the next year(s) after 2026, the company can leverage competitive positioning—an approach that is consistent with a 2027 support horizon. ²⁴

D. Resource intensity / reinvestment context (innovation as a pillar)

Management frames reinvestment in innovation and R&D as a “circle” where investments drive better growth and allow continued reinvestment and margin improvement, emphasizing that innovation “matters” as an “important pillar” of the Remainco strategy. ⁵
The excerpt provides an R&D intensity reference: the company indicates spending is “in that 8% to 9% range” of sales and stresses the need to “critically continue to reinvest” to set the company apart. ⁵

Bottom line

Recovery drivers: Fine Fragrance is recovering via management of Middle East uncertainty plus improved Q4 timing against difficult Q3 comps; Consumer Fragrance is supported by rebuilt R&D capability and customer go-to-market to regain share, while Fragrance Ingredients growth normalizes after a strong Q2 driven partly by favorable comps and a synthetics-led capture. ²¹³
H2 evolution:
- Fine Fragrance: mid-single-digit H2, softer Q3 and stronger Q4, with volatility and tough Q3 comparisons central to the shape. ²¹
- Consumer Fragrance: low-single-digit H2, with Q2’s high-single-digit rate expected to normalize downward. ²
R&D plan for 2027 support: management reports a materially improved R&D pipeline and capability (perfumers, molecules, delivery systems) and ties R&D to execution through customer go-to-market and market share gains; additionally, management frames innovation reinvestment (R&D at ~8%–9% of sales) as essential to building competitiveness into the 2027 timeframe. ⁴²⁵

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

Scent Recovery Drivers Drive IFF's H2 Outlook and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery drivers, H2 evolution by sub-segment, and 2027 R&D plan

1) Drivers of Scent’s recovery

A. Fine Fragrance: managing Middle East volatility + strong Q4 recovery shape

B. Consumer Fragrance: R&D rebuild + go-to-market + market share gains

C. Fragrance Ingredients: temporary normalization pressure after a very strong Q2

2) How Fine Fragrance and Consumer Fragrance will evolve in H2

Fine Fragrance (mid-single-digit H2; softer Q3, stronger Q4)

Consumer Fragrance (low-single-digit H2; Q2 strength normalizes)

3) Plan for R&D to support 2027 (what management says they changed and what it enables)

A. Current R&D state: pipeline, perfumers, delivery systems, and improved capability

B. What R&D is explicitly intended to accomplish (commercial execution + share gains)

C. Link to 2027 competitiveness: ingredient strategy maturation + R&D pipeline readiness

D. Resource intensity / reinvestment context (innovation as a pillar)

Bottom line

References

Keep Reading

IFF Scent Recovery Fueled by R&D Strength; 2H Outlook and 2027 Plan, Q2 2026

Keep Reading

Keep Reading

IFF Scent Recovery Fueled by R&D Strength; 2H Outlook and 2027 Plan, Q2 2026

IFF's Scent Recovery Gains Momentum with R&D and H2 Outlook for 2026

IFF's Scent Recovery Gains Momentum as R&D Lays 2027 Roadmap and 2H 2026 Outlook

IFF Sets Capex Target at 5-6% of Sales Post-Divestiture to Fund High-Return Initiatives

IFF Scent Recovery Driven by R&D Rebuild; Q2 2026 H2 Outlook and 2027 Plan

IFF's Scent Recovery Q2 2026 Highlights, H2 Outlook and 2027 R&D Plan

IFF Signals Scent Recovery Driven by R&D Rebuild and 2027 Plan

IFF Scent Recovery Driven by R&D Rebuild, Fragrance Momentum, and 2027 Plan

IFF's Scent Recovery Driven by R&D Rebuild, 2027 Readiness Ahead

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

IFF Scent Recovery Driven by R&D Rebuild, H2 Outlook, and 2027 Plan

IFF Scent Recovery Gains Momentum in Q2 2026 with Second-Half Outlook